All articles by Vidya Sagar Maddela
Vidya Sagar Maddela
Merck reports positive Phase 3 results for Enlicitide in hyperlipidemia
The CORALreef HeFH and CORALreef AddOn trials showed statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol (LDL-C) compared to placebo and other oral non-statin therapies.
EC approves fixed-duration Calquence regimens to treat CLL
The approval is based on positive results from the Phase 3 AMPLIFY trial, which showed significant improvement in progression-free survival for Calquence-based combinations.
Aytu BioPharma to commercialise Exxua antidepressant in US
Exxua is a first-in-class selective serotonin 5HT1a receptor agonist that has been approved by the US Food and Drug Administration (FDA) for major depressive disorder (MDD).
GSK invests $300,000 to help launch the Pharmacy Innovation in Immunization Research Collaborative (PIIRC) at the University of Waterloo School of Pharmacy
PIIRC serves as a catalyst for innovation by supporting interdisciplinary research and real-world evidence generation focused on improving vaccine access, delivery and education.
EC grants approval for paediatric myopia drug developed by Sydnexis
The EC approval follows a positive opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP), based on data from the STAR study, evaluating the drug in children aged three to 14 years
Allay Therapeutics secures $57.5m funding for ATX101 pain platform
The financing will support Allay’s Phase 2b registration trial of ATX101, a configuration of bupivacaine and a biopolymer targeting post-surgical pain relief following total knee replacement surgery
Juvenescence acquires AI drug discovery company Ro5 to boost R&D capabilities and drive pipeline of medicines to extend healthy lifespan
Juvenescence is a clinical-stage AI-enabled biotech company developing novel medicines to extend healthy lifespan. Our approach centers around developing medicines that target core aging mechanisms to treat and prevent age-related diseases.
Vividion acquires WRN inhibitor to enhance oncology pipeline
VVD-214 is a clinical-stage Werner helicase (WRN) inhibitor that targets cancers with high microsatellite instability (MSI), such as colorectal, endometrial, ovarian, and gastric cancers.
Molecular Health, Axxam partner to accelerate drug target discovery
The collaboration integrates Molecular Health’s AI-driven Dataome platform with Axxam’s DiscoveryMAXX process to advance the identification and validation of novel therapeutic targets
Oncovita receives FDA Orphan Drug Designation for its lead oncolytic virus candidate MVdeltaC in the treatment of pleural mesothelioma
Oncovita is a biotechnology spin-off from the Institut Pasteur, specializing in the development of virus-based immunotherapies for cancer, with a particular focus on platforms using the oncolytic measles virus